Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma
Ali Özdemir,Dilek Doğruel
DOI: https://doi.org/10.1159/000506595
2020-01-01
Medical Principles and Practice
Abstract:Objective: Systemic administration of magnesium sulphate (MgSO4) has been proposed as a treatment for pediatric patients with acute asthma. However, existing trials show mixed results and uncertain evidence of benefit. The aim of the study was to evaluate whether intravenous (IV) MgSO4 improves lung function measurements in children with acute asthma.Methods: This was a prospective clinical trial. All patients with acute asthma received 40-50 mg/kg or maximum 1,500 mg (>30 kg) of single dose IV MgSO4, administered over 60 minutes. Spirometry was obtained before and 15 minutes after MgSO4 infusion. Results: One hundred fifteen children aged 6 to 17 years presenting with acute asthma and FEV1 between 40% to 75% of predicted were included. Then, the patients were classified into 2 groups; mild asthma attack (FEV1 ranged 60% to 75%; n=50) or moderate asthma attack (FEV1 ranged 40% to 59%; n=65). The baseline characteristics were similar in both groups. The mean percent predicted pre and post values for FEV1/FVC ratio (mild group:82,59± 9,46 vs 85,06± 8,95; moderate group:77,31± 11,17 vs 79,99± 11,77), FEV1 (mild group:67,14 ± 4,99 vs 72,29± 8,05; moderate group:48,50 ± 6,81 vs 53,78± 9,81), PEF (mild group:65,49± 12,32 vs 71,37±12,96; moderate group: 47,56± 11,78 vs 51,97±13,98) and FEF25-75 (mild group:58,20±12,24 vs 66,57±16,95; moderate group:37,77± 11,37 vs 43,41±14,19) showed statistically significant (p<0.05 for all) bronchodilator effect after MgSO4 infusion in both groups with few side effects. Conclusion: Administration of IV MgSO4 was associated with improvement in pulmonary function in children with acute asthma.
medicine, general & internal